Loading…
Sectoral / Thematic · Nippon India Mutual Fund · AMFI code 102431Nippon India Pharma Fund
Disclosed for 84 months, Sep 2019 to Aug 2026.Published as: NIPPON INDIA PHARMA FUND (An Open Ended Equity Scheme Investing In Pharma Sector)
Portfolio value
₹4,261 Cr
up ₹102 Cr vs Feb 2021
- Stocks held
- 21
- unchanged
- Top 10 weight
- 82.4%
- of the portfolio in its ten largest
Nippon India Pharma Fund is an active equity fund in the Sectoral / Thematic category from Nippon India Mutual Fund. In March 2021 it disclosed 21 stocks worth ₹4,261 Cr, up ₹102 Cr from Feb 2021. Its largest positions were Sun Pharmaceutical Industries Limited (11.2%), Aurobindo Pharma Limited (9.9%), Dr. Reddy's Laboratories Limited (9.8%); the ten largest together made up 82.4% of the portfolio, and Pharmaceuticals & Biotechnology was the biggest sector at 79.7% of its equity. Cash and debt stood at 0.6%. Compared with Feb 2021 the fund entered 0 new stocks and exited 0.
Against 229 other Sectoral / Thematic funds
Concentration
98%
Top-10 weight is higher than 98% of peers
Breadth
6%
Holds more stocks than 6% of peers
Cash
9%
Holds more cash than 9% of peers
What these mean: concentration · cash
Holdings in March 2021
Download CSVEvery line the fund disclosed, with the change against Feb 2021. Click a column to sort; click a company to see every fund that owns it. New to these? How to read a portfolio.
| Sun Pharmaceutical Industries Limited | 11.23% | down 0.21 pts | ₹478 Cr | up ₹2.6 Cr | Added |
| Aurobindo Pharma Limited | 9.93% | down 0.35 pts | ₹423 Cr | down ₹4.6 Cr | Trimmed |
| Dr. Reddy's Laboratories Limited | 9.80% | down 0.04 pts | ₹418 Cr | up ₹8.3 Cr | Added |
| Cipla Limited | 9.76% | up 0.11 pts | ₹416 Cr | up ₹14.3 Cr | Added |
| Lupin Limited | 9.58% | down 0.46 pts | ₹408 Cr | down ₹9.3 Cr | Trimmed |
| Divi's Laboratories Limited | 8.93% | up 0.84 pts | ₹380 Cr | up ₹44.1 Cr | Added |
| Fortis Healthcare Limited | 7.28% | up 0.43 pts | ₹310 Cr | up ₹25.2 Cr | Added |
| Gland Pharma Limited | 6.39% | up 0.19 pts | ₹272 Cr | up ₹14.4 Cr | Added |
| Zydus Lifesciences Limited | 5.59% | up 0.36 pts | ₹238 Cr | up ₹20.5 Cr | Added |
| Thyrocare Technologies Limited | 3.92% | down 0.34 pts | ₹167 Cr | down ₹10.1 Cr | Trimmed |
| Narayana Hrudayalaya Limited | 3.60% | down 0.03 pts | ₹153 Cr | up ₹2.2 Cr | Added |
| Sanofi India Limited | 3.04% | up 0.07 pts | ₹129 Cr | up ₹6.1 Cr | Added |
| Abbott India Limited | 2.50% | up 0.04 pts | ₹106 Cr | up ₹4.2 Cr | Added |
| Indoco Remedies Limited | 2.27% | down 0.08 pts | ₹96.8 Cr | down ₹1.1 Cr | Trimmed |
| Apollo Hospitals Enterprise Limited | 2.05% | down 0.90 pts | ₹87.2 Cr | down ₹35.3 Cr | Trimmed |
| Jubilant Pharmova Limited | 1.45% | down 0.23 pts | ₹61.6 Cr | down ₹8 Cr | Trimmed |
| Torrent Pharmaceuticals Limited | 0.96% | up 0.90 pts | ₹40.7 Cr | up ₹38.3 Cr | Added |
| Cash, TREPS & receivables | 0.61% | down 0.32 pts | ₹26 Cr | down ₹12.8 Cr | Trimmed |
| Jubilant Ingrevia Limited | 0.55% | up 0.28 pts | ₹23.5 Cr | up ₹12.4 Cr | Added |
| Healthcare Global Enterprises Limited | 0.52% | up 0.05 pts | ₹22.1 Cr | up ₹2.5 Cr | Added |
| Alkem Laboratories Limited | 0.05% | down 0.13 pts | ₹2 Cr | down ₹5.4 Cr | Trimmed |
| Biocon Limited | 0.03% | down 0.16 pts | ₹1.2 Cr | down ₹6.8 Cr | Trimmed |
What changed, Feb 2021 to Mar 2021
New New positions (0)
None.
Exited Exited (0)
None.
Added Biggest additions
- Divi's Laboratories Limitedup ₹44.1 Cr (+0.84% pts)
- Torrent Pharmaceuticals Limitedup ₹38.3 Cr (+0.90% pts)
- Fortis Healthcare Limitedup ₹25.2 Cr (+0.43% pts)
- Zydus Lifesciences Limitedup ₹20.5 Cr (+0.36% pts)
- Gland Pharma Limited ₹14.4 Cr (+0.19% pts)
Sectors
Which sectors the fund is moving towards and away from, and where its money sits now. Shares are of the fund’s classified equity holdings, so they add up to 100%.
Where the weight moved
Compared with
Since Feb 2021, the weight rose most in Pharmaceuticals & Biotechnology (+0.7 pts) and Chemicals & Petrochemicals (+0.3 pts), and fell most in Healthcare Services (−0.9 pts).
- Pharmaceuticals & Biotechnology79.0% → 79.7%+0.7 pts
- Chemicals & Petrochemicals0.3% → 0.6%+0.3 pts
- Healthcare Services18.3% → 17.5%−0.9 pts
A sector’s weight changes when the fund buys or sells, and also when its shares rise or fall in price, so a change is not by itself a sign of buying or selling.
Main sectors’ weights over time
| Sector | Mar 2020 | Sep 2020 | Dec 2020 | Feb 2021 | Mar 2021 |
|---|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 78.4% | 79.0% | 79.4% | 79.0% | 79.7% |
| Healthcare Services | 19.4% | 18.7% | 18.2% | 18.3% | 17.5% |
| Pharmaceuticals | 2.2% | 2.3% | 2.4% | 2.4% | 2.3% |
| Chemicals & Petrochemicals | — | — | — | 0.3% | 0.6% |
Allocation in Mar 2021change vs Feb 2021
- Pharmaceuticals & Biotechnology (14)79.7%▲ 0.7 pts
- Healthcare Services (5)17.5%▼ 0.9 pts
- Pharmaceuticals (1)2.3%▼ 0.1 pts
- Chemicals & Petrochemicals (1)
Cash and debt
The share of the portfolio not in shares: cash and net receivables, money-market instruments and bonds, as disclosed each month. Cash can dip below zero when payables, often on derivative positions, exceed it. A change here describes what the fund did; it is not a signal. More on reading cash.
Cash & debt, Mar 2021
0.6%
▼ 0.3 pts vs Feb 2021
- Cash alone
- 0.6%
- cash and net receivables
- A year earlier
- 1.4%
- Mar 2020 · now ▼ 0.8 pts
- Last 12 months
- 0.6% – 4.5%
- lowest to highest · record 4.5% in Jul 2020
History
Disclosed portfolio value by month, with the stocks the fund entered and exited against its previous disclosure. Every month is a link to that portfolio.